Annual report pursuant to Section 13 and 15(d)

Concentration of Risk, Segment and Geographic Information - Revenue by Geographical Region (Details)

v3.10.0.1
Concentration of Risk, Segment and Geographic Information - Revenue by Geographical Region (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2018
 [1]
Sep. 30, 2018
 [1]
Jun. 30, 2018
 [1]
Mar. 31, 2018
 [1]
Dec. 31, 2017
 [2]
Sep. 30, 2017
 [2]
Jun. 30, 2017
 [2]
Mar. 31, 2017
 [2]
Dec. 31, 2018
Dec. 31, 2017
Revenues from External Customers and Long-Lived Assets [Line Items]                    
Revenues $ 1,685 $ 896 $ 2,255 $ 463 $ 5,357 $ 36,183 $ 10,890 $ 260 $ 5,299 $ 52,690
United States [Member]                    
Revenues from External Customers and Long-Lived Assets [Line Items]                    
Revenues                 3,935 1,654
Europe [Member]                    
Revenues from External Customers and Long-Lived Assets [Line Items]                    
Revenues                 1,014 50,936
Asia Pacific [Member]                    
Revenues from External Customers and Long-Lived Assets [Line Items]                    
Revenues                 $ 350 $ 100
[1] Total revenues include upfront fees, milestone payments and royalties relating to various out-licensing arrangements, which includes $1.8 million of revenue recognized in the second quarter of 2018 under the license agreement and common stock purchase agreement with Rezolute, and $0.8 million in milestone revenue earned in the fourth quarter of 2018 under our license agreement with Janssen Biotech, Inc.
[2] In the third quarter of 2017, total revenues include upfront and milestone payments relating to various out-licensing arrangements, including $35.4 million of license fee revenue recognized in connection with the license agreements with Novartis, and, in the second quarter of 2017, total revenues include a $10.0 million milestone earned under the license agreement with Novartis International.